EyePoint, Inc. Common Stock EYPT
Analyst Ratings
- Consensus
- Buy — 8 Buy · 1 Hold · 0 Sell (9 analysts)
- Avg. Price Target
- $41.88 (+759.9% upside)
Key Stats
- Today's Range
- $3.95 – $4.90
- 50-Day Range
- $3.95 – $15.92
- 52-Week Range
- $3.95 – $19.11
- Volume
- 52.27 million shs
- Average Volume
- 3.38 million shs
- Market Cap
- $1.27 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 7.64
- Price / Sales
- 455.94
Short Interest
- Short Interest
- 1.22%
- Days to Cover
- 2.36
Financials (TTM)
- Revenue
- $2.79 million
- Net Income
- $-306,643,000
- Net Margin
- -10994.73%
- Return on Equity
- -184.27%
- Debt-to-Equity
- —
About EyePoint, Inc. Common Stock
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Related Stocks
Compare head-to-head: EYPT vs WAT·EYPT vs BIO·EYPT vs BRKR·EYPT vs TXG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.